LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
Earnings & Valuation
This table compares LENZ Therapeutics and Silo Pharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENZ Therapeutics | $19.09 million | 7.44 | -$82.13 million | ($4.09) | -1.11 |
| Silo Pharma | $70,000.00 | 47.70 | -$4.23 million | ($4.36) | -0.48 |
Analyst Recommendations
This is a summary of current ratings and recommmendations for LENZ Therapeutics and Silo Pharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENZ Therapeutics | 1 | 2 | 5 | 0 | 2.50 |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
LENZ Therapeutics presently has a consensus price target of $28.80, suggesting a potential upside of 537.17%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe LENZ Therapeutics is more favorable than Silo Pharma.
Profitability
This table compares LENZ Therapeutics and Silo Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENZ Therapeutics | -586.74% | -53.39% | -49.14% |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
Institutional and Insider Ownership
54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 5.6% of Silo Pharma shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 3.6% of Silo Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
LENZ Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Summary
LENZ Therapeutics beats Silo Pharma on 10 of the 13 factors compared between the two stocks.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
